Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes